The management board, comprises two members from each of the partners with Professor Ian Jacobs acting as chair. The management board is responsible for prioritisation of the scientific objectives of the centre.
Professor Tracy Hussell
Following a successful career in the fields of mucosal immunology and infectious disease, Professor Tracy Hussell was awarded a Personal Chair in inflammatory disease at Imperial College London in 2006. She has since developed a vibrant research group studying immunity, pathology, and vaccination to influenza virus infection. She is the current Director of MCCIR.
Professor Ian Greer
Professor Greer is Dean of the Faculty of Biology, Medicine and Health & Vice President of The University of Manchester. Professor Ian Greer is a clinician scientist and leader of international note who joined Manchester in the summer of 2015 from the University of Liverpool. At Liverpool, he was Pro-Vice-Chancellor of the Faculty of Health & Life Sciences from 2010 and Provost responsible for research policy from 2013.
Professor Greer is also Director of the Manchester Academic Health Science Centre (MAHSC) and Chair of the Northern Health Science Alliance (NHSA), a partnership of the eight northern England research-intensive universities with their major partner NHS hospital trusts, and the four Northern Academic Health Sciences Networks.
His clinical practice and research focuses on medical disorders in pregnancy, and women’s vascular health, particularly in relation to haemostasis and thrombosis, and he has attracted over £10 million in funding during his career.
Professor Martin Humphries
Martin Humphries is Professor of Biochemistry in the Faculty of Biology, Medicine and Health, The University of Manchester. He has recently been elected as the Vice President of the Academy of Medical Sciences. Professor Humphries was elected as a member of the Academia Europaea in 2006.
Dr David Allen
Dr David Allen is the head of the Respiratory Therapy Area at GlaxoSmithKline (GSK) and is responsible for the identification of novel differentiated medicines and their progression to registration and launch. He leads a group of over 200 scientists and clinicians who exploit scientific innovations that have the potential to address the major unmet needs in diseases such as COPD, severe asthma, acute lung injury and idiopathic pulmonary fibrosis.
Dr Maarten Kraan
After training as a physiotherapist and rheumatologist, Dr Maarten Kraan completed a PHD on synovial tissue analysis. In 1998 he became an Associate Professor at the University of Amsterdam. Following various roles in the field, he became the global head of the inflammation translational medicine group at Roche in Nutley, NJ, in 2009. He joined Astrazeneca in 2010 as Senior Vice President and Head of the Respiratory & Inflammation iMed in Mölndal, Sweden.
Professor Rose Maciewicz
Professor Rose Maciewicz gained a PhD on structure and function of non-histone proteins in transcriptional regulation of hormone induced gene activation at Buffalo University in 1978. Her career has focused on early drug discovery and development, and translational medicine activities from in vivo animal models to human method development studies. She joined AstraZeneca in 1992 and is currently Chief Scientist within the Respiratory, Inflammation and AutoImmunity iMed.